Clinical trials: Septic Shock
Septic Shock
Midodrine Use in Septic Shock
The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.
- Trial name
- NCT03706053
- Testing
- Midodrine Hydrochloride
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Septic Shock
High MAP in Septic Shock With Hypertension
We hypothesized that the increase in MAP from 65 mmHg to patients' usual level improved sublingual microcirculation.
- Trial name
- NCT01443494
- Testing
- NE
- Where
- China
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Southeast University, China
Toxic Shock Syndrome
Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Toxic Shock Syndrome (TSS) is a severe condition with high morbidity and mortality from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02814708
- Testing
- rTSST-1v
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Toxic Shock Syndrome, Vaccination; Sepsis
rTSST-1 Variant Vaccine Phase 1 First-in-man Trail
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- rTSST-1 (NCT02340338)
- Testing
- rTSST-1 Variant Candidate Vaccine
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Toxic-Shock Syndrome, Sepsis
Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02971670
- Testing
- rTSST-1 Variant Candidate Vaccine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Sepsis, Septic Shock
Release of Nociceptin From Granulocytes in Sepsis
Nociceptin is a protein found in the body, with a number of functions in the central nervous system, blood vessels and the gut. There is evidence that it may have a role in controlling the immune response to infection, and may…
- Conditions
- Sepsis, Septic Shock, Sepsis Syndrome, Severe Sepsis
- Trial name
- NCT03037281
- Testing
- Septic
- Where
- 2 sites in United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Healthy Volunteer Safety Study
AB103 Peptide Antagonist in Healthy Volunteers
The primary objective of this study is to establish the safety profile and maximum tolerated dose (MTD) of AB103 given as a single intravenous (IV) infusion in healthy volunteers.
- Trial name
- NCT01166984
- Testing
- AB103
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Atox Bio Ltd